Overall survival

Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients

G. Zhong, Li, H. K., Shan, T., and Zhang, N., “Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients”, vol. 14, pp. 17228-17234, 2015.

We investigate whether three common polymorphisms in ERCC1 and ERCC2 are predictor factors for the chemotherapy response, as well as the clinic outcome of patients with gastric cancer. Between May 2011 and May 2013, 263 patients with gastric cancer who were newly diagnosed by histopathology were enrolled in our study. Genotyping of the ERCC1 rs11615 and rs3212986, and ERCC2 rs1799793 polymorphisms were conducted by the polymerase chain reaction-restriction fragment length polymorphism assay.

Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma

M. J. Wang, Zhu, Y., Guo, X. J., and Tian, Z. Z., “Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma”, vol. 14, pp. 11652-11657, 2015.

We conducted a perspective study to investigate the role of ERCC1 (rs11615), ERCC2 (rs13181 and rs1799793), ERCC4 (rs1800067), and ERCC5 (rs17655) in NER pathway in the prognosis of osteosarcoma patients. In total, 146 osteosarcoma patients were recruited between 2008 and 2013. ERCC1 rs11615, ERCC2 rs13181 and rs1799793, ERCC4 rs1800067, and ERCC5 rs17655 gene polymorphisms were assessed by polymerase chain reaction-restriction fragment length polymorphism assay.

Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma

Q. Zhang, Lv, L. Y., Li, B. J., Zhang, J., and Wei, F., “Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma”, vol. 14, pp. 11235-11241, 2015.

We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. A perspective study was conducted on 260 patients with osteosarcoma during 2010 and 2011. A polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was used to assess the ERCC1 rs11615 and rs3212986, and the ERCC2 rs1799793 and rs13181 gene polymorphisms.

Subscribe to Overall survival